Immuron Ltd has released a press release.
Appendix 4E Preliminary Final Report (30 June 2017)
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Immuron Opens Clinical Site to Commence C.Diff CDI Study
- Immuron Approved to Commence Clinical Study in C.Difficile
- Immuron to Present C.difficile Data at ClostPath 2017 Confer
- Immuron Announces Management Changes
- Success of NASH Phase II Interim Analysis Explained Further
Later from Immuron
- Travelan Experiences Strong Q1 FY2018 Sales Growth
- Immuron Successfully Completes NASH Phase II Clinical Study
- Immuron Granted US Patent for NASH Treatment
- Immuron to Receive $2.16M R&D Tax Concession Cash Refund
- US Defence Depart Report-Travelan Targets Priority Pathogens
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron